Research Centre of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
World J Gastroenterol. 2013 Jun 28;19(24):3792-801. doi: 10.3748/wjg.v19.i24.3792.
To investigate the effects of Annexin A2 (ANXA2) silencing on invasion, migration, and tumorigenic potential of hepatoma cells.
Human hepatoma cell lines [HepG2, SMMC-7721, SMMC-7402, and MHCC97-H, a novel human hepatocellular carcinoma (HCC) cell line with high metastasis potential] and a normal hepatocyte cell line (LO2) were used in this study. The protein and mRNA expression levels of ANXA2 were analysed by western blotting and real-time polymerase chain reaction, respectively. The intracellular distribution profile of ANXA2 expression was determined by immunofluorescence and immunohistochemistry. Short hairpin RNA targeting ANXA2 was designed and stably transfected into MHCC97-H cells. Cells were cultured for in vitro analyses or subcutaneously injected as xenografts in mice for in vivo analyses. Effects of ANXA2 silencing on cell growth were assessed by cell counting kit-8 (CCK-8) assay (in vitro) and tumour-growth assay (in vivo), on cell cycling was assessed by flow cytometry and propidium iodide staining (in vitro), and on invasion and migration potential were assessed by transwell assay and wound-healing assay, respectively (both in vitro).
The MHCC97-H cells, which are known to have high metastasis potential, showed the highest level of ANXA2 expression among the four HCC cell types examined; compared to the LO2 cells, the MHCC97-H expression level was 8-times higher. The ANXA2 expression was effectively inhibited (about 80%) by ANXA2-specific small hairpin RNA (shRNA). ANXA2 expression in the MHCC97-H cells was mainly localized to the cellular membrane and cytoplasm, and some localization was detected in the nucleus. Moreover, the proliferation of MHCC97-H cells was obviously suppressed by shRNA-mediated ANXA2 silencing in vitro, and the tumour growth inhibition rate was 38.24% in vivo. The percentage of MHCC97-H cells in S phase dramatically decreased (to 27.76%) under ANXA2-silenced conditions. Furthermore, ANXA2-silenced MHCC97-H cells showed lower invasiveness (percentage of invading cells decreased to 52.16%) and suppressed migratory capacity (migration distance decreased to 63.49%). It is also worth noting that shRNA-mediated silencing of ANXA2 in the MHCC97-H cells led to abnormal apoptosis.
shRNA-mediated silencing of ANXA2 suppresses the invasion, migration, and tumorigenic potential of hepatoma cells, and may represent a useful target of future molecular therapies.
研究 Annexin A2(ANXA2)沉默对肝癌细胞侵袭、迁移和致瘤能力的影响。
本研究使用人肝癌细胞系[HepG2、SMMC-7721、SMMC-7402 和 MHCC97-H,一种具有高转移潜能的新型人肝癌细胞系]和正常肝细胞系(LO2)。通过 Western blot 和实时聚合酶链反应分别分析 ANXA2 的蛋白和 mRNA 表达水平。通过免疫荧光和免疫组织化学确定 ANXA2 表达的细胞内分布情况。设计并稳定转染针对 ANXA2 的短发夹 RNA(shRNA)至 MHCC97-H 细胞。将细胞进行体外分析或作为异种移植物皮下注射到小鼠中进行体内分析。通过细胞计数试剂盒-8(CCK-8)测定(体外)和肿瘤生长测定(体内)评估 ANXA2 沉默对细胞生长的影响,通过流式细胞术和碘化丙啶染色(体外)评估细胞周期,通过 Transwell 测定和划痕愈合测定分别评估侵袭和迁移潜力(两者均为体外)。
在所检查的四种肝癌细胞类型中,具有高转移潜能的 MHCC97-H 细胞显示出最高水平的 ANXA2 表达;与 LO2 细胞相比,MHCC97-H 表达水平高 8 倍。ANXA2 特异性短发夹 RNA(shRNA)可有效抑制 ANXA2 表达(约 80%)。MHCC97-H 细胞中的 ANXA2 表达主要定位于细胞膜和细胞质,一些定位于细胞核。此外,shRNA 介导的 ANXA2 沉默在体外明显抑制 MHCC97-H 细胞的增殖,体内肿瘤生长抑制率为 38.24%。在 ANXA2 沉默条件下,MHCC97-H 细胞的 S 期比例明显下降(至 27.76%)。此外,ANXA2 沉默的 MHCC97-H 细胞侵袭率较低(侵袭细胞百分比降至 52.16%),迁移能力受抑制(迁移距离降至 63.49%)。值得注意的是,shRNA 介导的 MHCC97-H 细胞中 ANXA2 的沉默导致异常凋亡。
shRNA 介导的 ANXA2 沉默抑制肝癌细胞的侵袭、迁移和致瘤能力,可能成为未来分子治疗的有用靶点。